In diabetes mellitus, the global estimates of its prevalence are increasing each year, with T2DM accounting for approximately 90% of cases [1]. Although many antihyperglycemic agents have already been available for the treatment of T2DM, their glucose-lowering effects in the context of long-term glycemic control are not satisfactory [2]. There is an urgent need for more effective agents with fewer adverse effects to lower blood glucose. Sodium glucose cotransporter 2 (SGLT2) inhibitors are a novel kind of antihyperglycemic agent, approved by the US Food and Drug Administration (FDA) to use with diet and exercise to lower blood glucose in adults with type 2 diabetes. Medicines in the SGLT2 inhibitor category were first approved in 2013, including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin [3]. Ertugliflozin is the fourth SGLT2 inhibitor approved in the United States [4]. By decreasing the renal glucose threshold, therefore increasing urinary glucose excretion, the pharmacological inhibition of SGLT2 cotransporters reduces hyperglycemia, offering an effective way to treat T2DM patients [5]. Ertugliflozin as monotherapy [6] or in combination [7] with other antihyperglycemic agents has been associated with improvements in glycemic control, body weight, and blood pressure. However, in 2018, the FDA issued a warning that SGLT2 inhibitors reported cases of severe genital infections [3]. Although ertugliflozin has a good hypoglycemic effect, geni-
ertugliflozin, and the safety of ertugliflozin as a monotherapy at different periods with different doses was unclear and needs to be investigated.

Thus, we performed a meta-analysis of randomized controlled trials to assess the safety of ertugliflozin monotherapy at doses of 15 mg and 5 mg on GMIs, urinary tract infections (UTIs), drug-related adverse events, drug-related serious adverse events, discontinuation related to adverse events, deaths, symptomatic hypoglycemia, and hypovolemia at 26, 52, and 104 weeks. We also compared the effects of 15 mg ertugliflozin with a 5 mg dose on safety outcomes in each period. The registration number is CRD42020211388.

2. Materials and Methods

This study was conducted according to the Cochrane Collaboration and the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement [10, 11].

2.1. Eligibility Criteria. Studies satisfying the following criteria were included:

1. **Population**: patients were diagnosed as T2DM according to American Diabetes Association guidelines and were ≥18 years old and had glycated hemoglobin that was inadequately controlled with conventional therapy (metformin or diet and exercise).

2. **Intervention**: monotherapy ertugliflozin at doses of 15 mg and 5 mg with or without a background of metformin; the treatment period was 26, 52, or 104 weeks.

3. **Comparison**: other hypoglycemic agents or placebo.

4. **Outcome**: GMIs, UTIs, drug-related adverse events, drug-related serious adverse events, discontinuation-related adverse events, deaths, symptomatic hypoglycemia, and hypovolemia.

5. **Study design**: only randomized controlled trials (RCTs) were included.

6. **Language restrictions**: only studies published in English.

The exclusion criteria were as follows: patients with type 1 diabetes mellitus, a history of ketoacidosis, an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m², or a history of cardiovascular events within 3 months of screening.

2.2. Search Strategy. A systematic literature search about RCTs of ertugliflozin was conducted by two investigators (HJ and XSY) to identify relevant studies on PubMed, Embase, and The Cochrane Library from inception to September 23, 2020. The language was restricted to English. We also searched ClinicalTrials.gov and reviewed the references of the included articles to identify additional studies. The search terms included “diabet” and “ertugliflozin.” After eliminating the duplicates, the two investigators screened the titles and abstracts independently. Then, they performed a full-text evaluation. Meanwhile, discrepancies were referred to a third investigator and resolved through discussion (DSL).

2.3. Data Extraction. Data was extracted using a tailored form, including the following: the first author, publication year, NCT number, HbA1c% (baseline), the number of patients, intervention, and safety outcomes (primary: GMIs and UTIs; secondary: drug-related adverse events, drug-related serious adverse events, discontinuation related to adverse events, deaths, symptomatic hypoglycemia, and hypovolemia). The data selection procedure was performed independently by two investigators (HJ and XSY), and discrepancies were resolved through discussion among the three investigators (HJ, XSY, and DSL).

2.4. Risk of Bias and Strength of Evidence. The Cochrane Risk of Bias Tool was used to assess the risk of bias for included studies [12]. Each included study was assessed as “high,” “low,” or “unclear” risk of bias based on the following seven domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. Furthermore, the strength of evidence for each outcome (ertugliflozin group vs. control group) was judged as high, moderate, low, or very low according to the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) system [13], and each study’s quality was decreased based on risk of bias, inconsistency, indirectness, imprecision, and publication bias (GRADEpro GDT, https://gdt.gradepro.org/). Two investigators (HJ and XSY) reviewed and classified the RCTs independently. Differing opinions were resolved through discussions with a third investigator (DSL).

2.5. Statistical Analysis. Review Manager 5.3 was used for meta-analysis. Since all of the extracted data were dichotomous, risk ratio (RR) and 95% confidence interval (CI) were calculated to estimate effect size for dichotomous variables. p values <0.05 were deemed statistically significant. The backgrounds of the patients and control groups of included studies were not homogeneous. Taking into account the heterogeneity between studies, a random effects model was used to aggregate data to promote the generality of the results. A sensitivity analysis was performed by excluding studies one by one. Due to the small number of included studies, subgroup analysis and publication bias test were not performed [10].

3. Results

3.1. Trial Selection. 381 articles were identified in the database retrieval. Among them, 82 articles were excluded after removing duplicates. In addition, 14 records were identified through other sources. After screening by title and abstract, 11 of the remaining 313 articles were selected for full-text assessment. Ultimately, 9 articles [6, 14–21] (6 NCT numbers) were included in the study (NCT numbers: 02630706 [14], 01999218 [15, 18], 02033889 [6, 16], 01958671 [20, 21], and 02099110 [17], and 02036515 [19]). A flow chart reflecting the literature search process is shown in Figure 1.
3.2. Study Characteristics. This meta-analysis included six studies that were published from 2017 to 2019, enrolling 4120 participants. Three studies [17, 19–21] were conducted over 52 weeks with two 26-week periods (phase A and phase B). One study [15, 18] was conducted over 104 weeks with two 52-week periods (phase A and phase B). One study [6, 16] was conducted over 104 weeks with a 26-week period (phase A) and a 78-week period (phase B), and another study [14] was conducted over 26 weeks. Participants in one study [20, 21] were T2DM patients whose diabetes was inadequately controlled by diet and exercise. Other participants were T2DM patients whose diabetes was inadequately controlled by metformin monotherapy or combination metformin and sitagliptin. Among the six included studies, four [6, 14, 16, 19–21] compared 15 mg and 5 mg ertugliflozin monotherapy with placebo, one [15, 18] compared 15 mg and 5 mg ertugliflozin monotherapy with glimepiride, and the remaining one [17] compared 15 mg and 5 mg ertugliflozin monotherapy with sitagliptin and coadministrations. Detailed characteristics of included trials are shown in Table 1.

3.3. Risk of Bias Assessment. According to the Cochrane Risk of Bias Tool [12], three studies were assessed as low risk [15, 17, 18, 20, 21]. The randomization methods were explained in the included studies. Of these, a central electronic randomization system, an interactive automated system, and an interactive voice response system were used in the three studies, while allocation concealment of the remaining three studies was unclear. The data on ClinicalTrials.gov were also reviewed to confirm that blindness was applied during each study. The results are shown in Figures 2 and 3. Green represents a low risk of bias, yellow represents an unclear risk of bias, and red represents a high risk of bias.

3.4. Meta-Analysis Results

3.4.1. Ertugliflozin vs. Control

(1) Primary Outcomes. At 26, 52, and 104 weeks, the risk of GMIs was higher in the 15 mg and 5 mg ertugliflozin groups than that in the control group (Figure 4). For GMIs, the leave-one-out sensitivity analysis showed that the results of our meta-analysis were not significantly unstable (Table 2). Considering that the control groups of Hollander et al. [18] and Pratley et al. [17] used glimepiride and sitagliptin, while other studies used placebo, we deleted both studies at 52 weeks and found that after deleting these two studies, the p value changed from <0.05 to >0.05 in the ertugliflozin 5 mg group.

No significant differences were found in the risk of UTIs at 26, 52, or 104 weeks (Figure 5). For UTIs, the leave-one-out sensitivity analysis showed that the results of our meta-analysis were not significantly unstable (Supplementary Table 1). After removing two studies that were not placebo-
controlled at 52 weeks, the sensitivity analysis showed that the results of our meta-analysis were not significantly unstable.

(2) Secondary Outcomes. At 26 weeks, the 15 mg and 5 mg ertugli
tofin groups had a higher risk of drug-related adverse events compared with the control group [(RR = 1.61; 95% CI, 1.19-2.15; \(p = 0.002\)) and (RR = 1.74; 95% CI, 1.22-2.49; \(p = 0.002\)), respectively] (Supplementary Figure 1). For drug-related adverse events, the leave-one-out sensitivity analysis showed that after removing Aronson et al. [20], the \(p\) value changed from >0.05 to <0.05 in the 15 mg ertugli
tofin group at 52 weeks (Supplementary Table 2).

**Table 1: Characteristics of studies included in the meta-analysis.**

| First author (year) | NCT number | Number of patients (E5/E15/C) | Baseline HbA1c | Intervention | Control | Periods |
|---------------------|------------|-------------------------------|---------------|--------------|---------|---------|
| Ji (2019) [14]      | NCT: 02630706 | 170/169/167                  | 7.0-10.5%     | 1. Ertugli
tofin 5 mg; 2. ertugli
tofin 15 mg GRT: glimepiride | Placebo | 26 weeks |
| Rosenstock (2018) [6], Gallo (2019) [16] | NCT: 02033889 | 207/205/209                  | 7.0-10.5%     | 1. Ertugli
tofin 5 mg; 2. ertugli
tofin 15 mg GRT: glimepiride (1-26 weeks), basal insulin (27-104 weeks) | Placebo | 26 weeks, 104 weeks |
| Hollander (2018) [18], Hollander (2019) [15] | NCT: 01999218 | 488/440/437                  | 7.0-9.0%      | 1. Ertugli
tofin 5 mg; 2. ertugli
tofin 15 mg GRT: sitagliptin (1-52 weeks), not permitted (53-104 weeks) | Glimepiride up to 6 or 8 mg/d | 52 weeks, 104 weeks |
| Pratley (2018) [17] | NCT: 02099110 | 250/248/247                  | 7.5-11%       | 1. Ertugli
tofin 5 mg; 2. ertugli
tofin 15 mg GRT: glimepiride or glargine | Sitagliptin 100 mg | 26 weeks, 52 weeks |
| Terra (2017) [21], Aronson (2018) [20] | NCT: 01958671 | 156/152/153                  | 7.0-10.5%     | 1. Ertugli
tofin 5 mg; 2. ertugli
tofin 15 mg GRT: metformin (1-26 weeks), glimepiride (27-52 weeks) | Placebo (1-26 weeks), metformin (27-52 weeks) | 26 weeks, 52 weeks |
| Dagogo-Jack (2018) [19] | NCT: 02036515 | 156/153/153                  | 7.0-10.5%     | 1. Ertugli
tofin 5 mg; 2. ertugli
tofin 15 mg GRT: glimepiride or glargine | Placebo | 26 weeks, 52 weeks |

E5: ertugli
tofin 5 mg; E15: ertugli
tofin 15 mg; C: control; GRT: glycemic rescue therapy.

**Figure 2: Risk of bias summary.**
Compared with the control group, at 104 weeks, the risk of discontinuation related to adverse events in the 15 mg ertugliozin group was higher (RR = 1.62; 95% CI, 1.05-2.50; p = 0.03) (Supplementary Figure 2; sensitivity analysis was shown in Supplementary Table 3), while the risk of symptomatic hypoglycemia in the 15 mg and 5 mg ertugliozin groups was lower [(RR = 0.33; 95% CI, 0.23-0.47; p < 0.00001) and (RR = 0.27; 95% CI, 0.11-0.66; p = 0.004), respectively] (Supplementary Figure 3; sensitivity analysis was shown in Supplementary Table 4). For discontinuation related to adverse events, the leave-one-out sensitivity analysis showed that after removing Gallo et al. [16] or Hollander et al. [15], the p value changed from <0.05 to >0.05 in the 15 mg ertugliozin group at 104 weeks.

No significant differences were found in the risk of drug-related serious adverse events, deaths, and hypovolemia at any week (Supplementary Figures 4-6; sensitivity analysis was shown in Supplementary Tables 5 and 6).

3.5. GMI (Female) vs. GMI (Male). When comparing the risk of GMI between females and males, we found that females had a higher risk of GMI than males in the 15 mg group at 26 weeks (RR = 2.58; 95% CI, 1.49-4.49; p = 0.0008), 52 weeks (RR = 3.07; 95% CI, 1.75-5.37; p < 0.0001), and 104 weeks (RR = 3.00; 95% CI, 1.18-7.64; p = 0.02) (Figure 6). However, in the 5 mg group at 26 weeks and 52 weeks, the p value changed from >0.05 to <0.05 after excluding Pratley et al. [17] (sensitivity analysis was shown in Supplementary Table 7).

3.5.1. Dose of 15 mg vs. That of 5 mg. When the 15 mg group compared with the 5 mg group, no significant differences were found in the risk of GMI (Figure 7), UTIs, drug-related adverse events, discontinuation related to adverse events, deaths, symptomatic hypoglycemia, and hypovolemia in this study at either 26, 52, or 104 weeks (Supplementary Figures 7-13). We also compared the risk of GMI between 15 mg and 5 mg groups by gender and found that there was no significant difference (Supplementary Figure 14). The leave-one-out sensitivity analysis showed that the results of our meta-analysis were not significantly unstable (sensitivity analysis was shown in Supplementary Tables 8-14).

3.6. Assessment of Quality of Evidence. Compared with the control group, the quality of evidence for the risk of GMIs in the 15 mg ertugliozin group at 26, 52, and 104 weeks was all low, and the quality of evidence for the risk of GMIs in the 5 mg ertugliozin group at 26, 52, and 104 weeks was also all low due to the small sample size, small number of included studies, and publication bias. The GRADE evidence profiles (ertugliozin vs. control) are provided in Supplementary Tables 15 and 16.

4. Discussion

In this meta-analysis, we systematically reviewed current studies and found that ertugliozin treatment had a higher risk for GMIs at every period compared with the control group. In particular, females showed a high risk for GMIs compared with males in the 15 mg ertugliozin group. We also found that ertugliozin decreased the risk for symptomatic hypoglycemia in a long course of treatment. There were no significant differences in the risk for UTIs, drug-related serious adverse events, deaths, or hypovolemia between the ertugliozin group and control group, and there were also no significant differences between the two doses. In summary, a high risk for GMIs is the most prominent problem of ertugliozin, especially among females in the high-dose group.

Diabetes patients are more susceptible to infections than nondiabetic patients. Possible causes include immune deficiency, increased adhesion of microorganisms to epithelial cells, the presence of complications, and extensive medical interventions [22]. Of the included studies, all six RCTs reported that ertugliozin can effectively control blood glucose, reduce body weight, and improve systolic blood pressure, so the efficacy of ertugliozin for T2DM that is otherwise inadequately controlled by conventional therapy is worthy of recognition. However, we noticed that the incidence of GMIs in the ertugliozin group was significantly higher than that in the control group. The mechanism of
SGLT2 inhibitors is considered to be the possible cause. SGLT2 inhibitors reduce blood glucose by reducing the reabsorption of glucose, so the glucose in the urine rises [23]. The increase of glucose in urine may increase the colonization rate of vaginal Candida [24] and the growth rate of urinary tract pathogens [25, 26], thereby increasing the risk of genital tract pathogens [25, 26], thereby increasing the risk of genital...
infections. In this study, we did not find that ertugliflozin increased the risk of UTIs compared with the control group. Among a variety of SGLT2 inhibitors, dapagliflozin produced a higher risk of UTIs than placebo and other active treatments, and it appeared to have a dose-response relationship for risk of UTIs and genital infections [27, 28]. However, patients with familial renal glucosuria rarely have UTIs [29]. It seems that urine glucose will increase the risk of GMIs, and UTIs in diabetic patients remain to be further studied [27].

A previous meta-analysis evaluated the efficacy and safety of SGLT2 inhibitors (ipragliflozin, dapagliflozin, canagliflozin, and empagliflozin), and this study showed that SGLT2 inhibitors could effectively control blood glucose, reduce body weight, and improve systolic blood pressure, but it also increased the risk of GMIs [30]. Three other meta-analyses also showed that SGLT2 inhibitors increased the risk of genital infections [27, 31, 32], and one of them showed that SGLT2 inhibitors had a net protective effect on cardiovascular outcomes and death [32].

Table 2: a: Leave-one-out sensitivity analysis for GMIs (ertugliflozin vs. control). b: Sensitivity analysis by excluding two studies that were not placebo-controlled.

| Study excluded | RR (95% CI) | Z-test p value | Heterogeneity ($I^2$) |
|---------------|-------------|----------------|----------------------|
| a 15 mg vs. control 26 weeks | | | |
| Dagogo-Jack (2018) [19] | 4.42 (1.96, 10.00) | $p = 0.0004$ | $p = 0.33; I^2 = 12\%$ |
| Ji (2019) [14] | 5.98 (2.84, 12.56) | $p < 0.0001$ | $p = 0.53; I^2 = 0\%$ |
| Pratley (2018) [17] | 4.34 (1.99, 9.47) | $p = 0.0002$ | $p = 0.36; I^2 = 8\%$ |
| Rosenstock (2018) [6] | 4.62 (1.93, 11.03) | $p = 0.0006$ | $p = 0.29; I^2 = 20\%$ |
| Terra (2017) [21] | 6.39 (2.12, 19.27) | $p = 0.0010$ | $p = 0.28; I^2 = 21\%$ |
| 5 mg vs. control 26 weeks | | | |
| Dagogo-Jack (2018) [19] | 3.67 (1.73, 7.77) | $p = 0.0007$ | $p = 0.38; I^2 = 2\%$ |
| Ji (2019) [14] | 4.74 (2.21, 10.15) | $p < 0.0001$ | $p = 0.40; I^2 = 0\%$ |
| Pratley (2018) [17] | 3.55 (1.70, 7.42) | $p = 0.0008$ | $p = 0.46; I^2 = 0\%$ |
| Rosenstock (2018) [6] | 3.77 (1.73, 8.26) | $p = 0.0009$ | $p = 0.36; I^2 = 7\%$ |
| Terra (2017) [21] | 5.93 (2.25, 15.58) | $p = 0.0003$ | $p = 0.46; I^2 = 0\%$ |
| 15 mg vs. control 52 weeks | | | |
| Aronson (2018) [20] | 9.32 (4.03, 21.52) | $p < 0.00001$ | $p = 0.91; I^2 = 0\%$ |
| Dagogo-Jack (2018) [19] | 5.24 (2.44, 11.27) | $p < 0.0001$ | $p = 0.23; I^2 = 33\%$ |
| Hollander (2018) [18] | 4.73 (2.14, 10.44) | $p = 0.0001$ | $p = 0.29; I^2 = 19\%$ |
| Pratley (2018) [17] | 5.82 (2.27, 14.93) | $p = 0.0002$ | $p = 0.16; I^2 = 45\%$ |
| 5 mg vs. control 52 weeks | | | |
| Aronson (2018) [20] | 8.66 (3.74, 20.06) | $p < 0.00001$ | $p = 0.89; I^2 = 0\%$ |
| Dagogo-Jack (2018) [19] | 4.73 (2.00, 11.16) | $p = 0.0004$ | $p = 0.17; I^2 = 44\%$ |
| Hollander (2018) [18] | 4.51 (1.74, 11.70) | $p = 0.002$ | $p = 0.21; I^2 = 37\%$ |
| Pratley (2018) [17] | 5.35 (1.85, 15.42) | $p = 0.002$ | $p = 0.11; I^2 = 55\%$ |
| 15 mg vs. control 104 weeks | | | |
| Gallo (2019) [16] | 11.67 (3.62, 37.65) | $p < 0.0001$ | NA |
| Hollander (2019) [15] | 5.44 (1.61, 18.38) | $p = 0.006$ | NA |
| 5 mg vs. control 104 weeks | | | |
| Gallo (2019) [16] | 10.43 (3.22, 33.80) | $p < 0.0001$ | NA |
| Hollander (2019) [15] | 4.38 (1.27, 15.13) | $p = 0.02$ | NA |

b 15 mg vs. control 52 weeks

Hollander (2018) [18]; Pratley (2018) [17] 4.73 (1.29, 17.39) $p = 0.02$ $p = 0.18; I^2 = 43\%$

5 mg vs. control 52 weeks

Hollander (2018) [18]; Pratley (2018) [17] 4.41 (0.94, 20.64) $p = 0.06$ $p = 0.13; I^2 = 56\%$

RR: risk ratio; CI: confidence interval; NA: not available.
is widely accepted that SGLT2 inhibitors can increase the risk for GMIs, which is consistent with our findings. However, a study in China showed that empagliflozin did not increase the risk for GMIs and UTIs [33]. The safety of different SGLT2 inhibitors may be different, and the difference is worthy of further exploration. A pooled analysis from three phase III clinical trials showed that ertugliflozin had a higher rate of GMIs and drug-related adverse events, but it had no significant effect on other safety outcomes [9]. We included these studies in our analysis. Another pooled analysis of canagliflozin, dapagliflozin, and empagliflozin showed that SGLT2 inhibitors had similar relative risks in females and males, and all of them increased the risk for GMIs, but there were no sex

is widely accepted that SGLT2 inhibitors can increase the risk for GMIs, which is consistent with our findings. However, a study in China showed that empagliflozin did not increase the risk for GMIs and UTIs [33]. The safety of different SGLT2 inhibitors may be different, and the difference is worthy of further exploration. A pooled analysis from three phase III clinical trials showed that ertugliflozin had a higher rate of GMIs and drug-related adverse events, but it had no significant effect on other safety outcomes [9]. We included these studies in our analysis. Another pooled analysis of canagliflozin, dapagliflozin, and empagliflozin showed that SGLT2 inhibitors had similar relative risks in females and males, and all of them increased the risk for GMIs, but there were no sex

is widely accepted that SGLT2 inhibitors can increase the risk for GMIs, which is consistent with our findings. However, a study in China showed that empagliflozin did not increase the risk for GMIs and UTIs [33]. The safety of different SGLT2 inhibitors may be different, and the difference is worthy of further exploration. A pooled analysis from three phase III clinical trials showed that ertugliflozin had a higher rate of GMIs and drug-related adverse events, but it had no significant effect on other safety outcomes [9]. We included these studies in our analysis. Another pooled analysis of canagliflozin, dapagliflozin, and empagliflozin showed that SGLT2 inhibitors had similar relative risks in females and males, and all of them increased the risk for GMIs, but there were no sex
infections caused by SGLT2 inhibitors was generally mild in comparison with our results. Although the intensity of genital infections with SGLT2 inhibitor therapy [35], which is consistent with the data, prior genital infections were at higher risk of genital infections [34]. This may be because there is no grouping based on the dose and follow-up time of the agent. However, a cohort study showed that female patients with prior genital infection were at higher risk of genital infections with SGLT2 inhibitor therapy [35], which is consistent with our results. Although the intensity of genital infections caused by SGLT2 inhibitors was generally mild or moderate, they tended to recur and eventually lead to treatment discontinuation and may even cause the risk of a rapid decline of renal function in some patients [26]. Therefore, genital infections should be paid attention to. In the long run, we found that ertugliflozin was not prone to cause symptomatic hypoglycemia, which may be because SGLT2 inhibitors lower blood glycemic levels on 26, 52, and 104 weeks. CI: confidence interval; M-H: Mantel-Haenszel.

![Figure 6: Forest plot of the risk of GMI when comparing females with males at 26, 52, and 104 weeks.](image-url)

| Study or subgroup | Female Events Total | Male Events Total | Weight | Risk ratio M-H, random, 95% CI | Risk ratio M-H, random, 95% CI |
|------------------|--------------------|------------------|--------|-------------------------------|-------------------------------|
| 1.4.1 Female vs. Male 26 weeks (15 mg) | | | | | |
| Dagogo-Jack 2018 | 9 | 71 | 3 | 82 | 3.3% | 3.46 [0.98, 12.31] | |
| Ji 2019 | 1 | 71 | 2 | 98 | 1.1% | 0.69 [0.06, 7.46] | |
| Pratley 2018 | 8 | 114 | 5 | 134 | 4.5% | 1.88 [0.63, 5.59] | |
| Rosenvold 2018 | 7 | 112 | 3 | 93 | 3.2% | 1.94 [0.52, 7.28] | |
| Terra 2017 | 14 | 62 | 5 | 90 | 5.4% | 4.06 [1.54, 10.71] | |
| Subtotal (95% CI) | 430 | 497 | 17.7% | 2.58 [1.49, 4.49] | |
| Total events | 39 | 18 | | | |
| Heterogeneity: Tau² = 0.00; Chi² = 2.74, df = 4 (p = 0.60); I² = 0% |
| Test for overall effect: Z = 3.37 (p = 0.0008) |
| 1.4.2 Female vs. Male 26 weeks (5 mg) | | | | | |
| Dagogo-Jack 2018 | 6 | 75 | 4 | 81 | 3.7% | 1.62 [0.48, 5.52] | |
| Ji 2019 | 2 | 75 | 2 | 95 | 1.6% | 1.27 [0.18, 8.78] | |
| Pratley 2018 | 6 | 123 | 6 | 127 | 4.4% | 1.03 [0.34, 3.11] | |
| Rosenvold 2018 | 6 | 110 | 3 | 97 | 3.1% | 1.76 [0.45, 6.86] | |
| Terra 2017 | 11 | 67 | 3 | 89 | 3.6% | 4.87 [1.41, 16.77] | |
| Subtotal (95% CI) | 496 | 497 | 20.8% | 3.07 [1.75, 5.37] | |
| Total events | 31 | 21 | | | |
| Heterogeneity: Tau² = 0.07; Chi² = 3.80, df = 3 (p = 0.28); I² = 21% |
| Test for overall effect: Z = 2.00 (p = 0.05) |
| 1.4.3 Female vs. Male 52 weeks (15 mg) | | | | | |
| Aronson 2018 | 18 | 62 | 7 | 90 | 7.1% | 3.73 [1.66, 8.40] | |
| Dagogo-Jack 2018 | 10 | 71 | 3 | 82 | 3.5% | 3.85 [1.10, 13.44] | |
| Hollander 2018 | 25 | 249 | 4 | 191 | 4.9% | 4.79 [1.70, 13.54] | |
| Pratley 2018 | 8 | 114 | 7 | 134 | 5.3% | 1.34 [0.50, 3.59] | |
| Subtotal (95% CI) | 496 | 497 | 20.8% | 3.07 [1.75, 5.37] | |
| Total events | 61 | 21 | | | |
| Heterogeneity: Tau² = 0.52; Chi² = 8.91, df = 3 (p = 0.03); I² = 66% |
| Test for overall effect: Z = 1.74 (p = 0.08) |
| 1.4.4 Female vs. Male 52 weeks (5 mg) | | | | | |
| Aronson 2018 | 18 | 67 | 3 | 89 | 3.9% | 7.97 [2.45, 25.95] | |
| Dagogo-Jack 2018 | 9 | 75 | 4 | 81 | 4.2% | 2.43 [0.78, 7.56] | |
| Hollander 2018 | 17 | 221 | 10 | 227 | 7.8% | 1.75 [0.82, 3.73] | |
| Pratley 2018 | 6 | 123 | 8 | 127 | 4.9% | 0.77 [0.28, 2.17] | |
| Subtotal (95% CI) | 486 | 524 | 20.9% | 2.16 [0.91, 5.17] | |
| Total events | 50 | 25 | | | |
| Heterogeneity: Tau² = 0.52; Chi² = 8.91, df = 3 (p = 0.03); I² = 66% |
| Test for overall effect: Z = 1.74 (p = 0.08) |
| 1.4.5 Female vs. Male 104 weeks (15 mg) | | | | | |
| Gollo 2019 | 11 | 112 | 5 | 93 | 5.0% | 1.83 [0.66, 5.07] | |
| Hollander 2019 | 30 | 244 | 5 | 191 | 5.8% | 4.70 [1.86, 11.88] | |
| Subtotal (95% CI) | 356 | 284 | 10.8% | 3.00 [1.18, 7.64] | |
| Total events | 41 | 10 | | | |
| Heterogeneity: Tau² = 0.21; Chi² = 1.84, df = 1 (p = 0.18); I² = 46% |
| Test for overall effect: Z = 2.31 (p = 0.02) |
| 1.4.6 Female vs. Male 104 weeks (5 mg) | | | | | |
| Gollo 2019 | 8 | 110 | 5 | 97 | 4.5% | 1.41 [0.48, 4.17] | |
| Hollander 2019 | 20 | 218 | 12 | 227 | 8.9% | 1.74 [0.87, 3.46] | |
| Subtotal (95% CI) | 328 | 324 | 13.4% | 1.63 [0.91, 2.93] | |
| Total events | 28 | 17 | | | |
| Heterogeneity: Tau² = 0.06; Chi² = 0.10, df = 1 (p = 0.75); I² = 0% |
| Test for overall effect: Z = 1.65 (p = 0.10) |
| Total (95% CI) | 2546 | 2615 | 100.0% | 2.29 [1.78, 2.95] | |
| Total events | 250 | 109 | | | |
| Heterogeneity: Tau² = 0.06; Chi² = 25.45, df = 21 (p = 0.23); I² = 17% |
| Test for subgroup differences: Chi² = 3.47, df = 5 (p = 0.65); I² = 0% |
Heterogeneity: Tau^2 = 0.00; Chi^2 = 0.66, df = 4 (p = 0.96); I^2 = 0%
Test for overall effect: Z = 0.91 (p = 0.36)

1.2.2 15 mg vs. 5 mg 52 weeks
Aronson 2018 25 152 21 156 13.8% 1.22 [0.72, 2.09]
Daggo-Jack 2018 13 153 13 156 7.3% 1.02 [0.49, 2.13]
Hollander 2018 29 440 27 448 15.4% 1.09 [0.66, 1.82]
Pratley 2018 15 248 14 250 7.9% 1.08 [0.53, 2.19]
Subtotal (95% CI) 993 1010 44.4% 1.12 [0.83, 1.50]
Total events 82 75
Heterogeneity: Tau^2 = 0.00; Chi^2 = 0.18, df = 3 (p = 0.98); I^2 = 0%
Test for overall effect: Z = 0.72 (p = 0.47)

1.2.3 15 mg vs. 5 mg 104 weeks
Gallo 2019 16 205 13 207 7.9% 1.24 [0.61, 2.52]
Hollander 2019 35 415 32 445 18.6% 1.12 [0.71, 1.77]
Subtotal (95% CI) 640 652 26.6% 1.15 [0.78, 1.70]
Total events 51 45
Heterogeneity: Tau^2 = 0.00; Chi^2 = 0.06, df = 1 (p = 0.81); I^2 = 0%
Test for overall effect: Z = 0.73 (p = 0.47)

Total (95% CI) 2560 2601 100.0% 1.15 [0.94, 1.40]
Total events 190 169
Heterogeneity: Tau^2 = 0.00; Chi^2 = 0.96, df = 10 (p = 1.00); I^2 = 0%
Test for overall effect: Z = 1.35 (p = 0.18)
Test for subgroup differences: Chi^2 = 0.07, df = 2 (p = 0.97); I^2 = 0%

Favours [15 mg] Favours [5 mg]

Figure 7: Forest plot of the risk of GMIs when comparing ertugliflozin 15 mg with 5 mg at 26, 52, and 104 weeks. CI: confidence interval; M-H: Mantel-Haenszel.

independent of pancreatic β cell function and insulin resistance [36]. However, there were only two [15, 16] studies that reported symptomatic hypoglycemia at 104 weeks, and Gallo et al.’s [16] control group was placebo while Hollander et al.’s [15] control group was glimepiride. Glimepiride is a sulfonylurea hypoglycemic agent, and the common adverse reaction is hypoglycemia [37]. Some studies have found that the risk for hypoglycemia of glimepiride is higher than that of SGLT2 inhibitors [38]. Thus, the difference in efficacy between glimepiride and placebo may be the source of heterogeneity.

The quality of evidence in this study is from very low to low. The reason for the low level of evidence is mainly due to insufficient sample size in each period, and the interventions of the control group included in the study are not homogeneous. This is also the limitation of this research. In the future, more large-scale clinical studies need to be focused.

Based on the results of our research, in future clinical practice using ertugliflozin, we should pay special attention to high risk for GMIs, especially females on high dosages of ertugliflozin. For patients on ertugliflozin, we should advocate for early prevention of GMIs. For example, patients with a history of genital infections should closely observe the occurrence of GMIs after weighing the advantages and disadvantages, and all patients should be more vigilant with their management of genital hygiene.

5. Conclusion

In general, ertugliflozin is effective and tolerated for T2DM inadequately controlled by conventional therapy, but the risk for GMIs is noteworthy, especially among females in the high-dose group. However, further research is necessary to clarify the long-term safety and the potential benefits and risks of this agent.

Data Availability

Data can be obtained from the original research articles included in this study. In addition, the data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.
Acknowledgments

The author would like to thank Mr. Xiao (a librarian of Chongqing Medical University) for professional technical support.

Supplementary Materials

**Supplementary 1.** Supplementary Figure 1: forest plot of the risk of drug-related adverse events (ertugliﬂozin vs. control). CI: confidence interval; M-H: Mantel-Haenszel.

**Supplementary 2.** Supplementary Figure 2: forest plot of the risk of discontinuation-related adverse events (ertugliﬂozin vs. control). CI: confidence interval; M-H: Mantel-Haenszel.

**Supplementary 3.** Supplementary Figure 3: Forest plot of the risk of symptomatic hypoglycemia (ertugliﬂozin vs. control). CI: confidence interval; M-H: Mantel-Haenszel.

**Supplementary 4.** Supplementary Figure 4: forest plot of the risk of drug-related serious adverse events (ertugliﬂozin vs. control). CI: confidence interval; M-H: Mantel-Haenszel.

**Supplementary 5.** Supplementary Figure 5: forest plot of the risk of deaths (ertugliﬂozin vs. control). CI: confidence interval; M-H: Mantel-Haenszel.

**Supplementary 6.** Supplementary Figure 6: forest plot of the risk of hypovolemia (ertugliﬂozin vs. control). CI: confidence interval; M-H: Mantel-Haenszel.

**Supplementary 7.** Supplementary Figure 7: forest plot the risk of UTIs (15 mg vs. 5 mg). CI: confidence interval; M-H: Mantel-Haenszel.

**Supplementary 8.** Supplementary Figure 8: forest plot the risk of drug-related adverse events (15 mg vs. 5 mg). CI: confidence interval; M-H: Mantel-Haenszel.

**Supplementary 9.** Supplementary Figure 9: forest plot the risk of drug-related serious adverse events (15 mg vs. 5 mg). CI: confidence interval; M-H: Mantel-Haenszel.

**Supplementary 10.** Supplementary Figure 10: forest plot the risk of discontinuation-related adverse events (15 mg vs. 5 mg). CI: confidence interval; M-H: Mantel-Haenszel.

**Supplementary 11.** Supplementary Figure 11: forest plot the risk of deaths (15 mg vs. 5 mg). CI: confidence interval; M-H: Mantel-Haenszel.

**Supplementary 12.** Supplementary Figure 12: forest plot the risk of symptomatic hypoglycemia (15 mg vs. 5 mg). CI: confidence interval; M-H: Mantel-Haenszel.

**Supplementary 13.** Supplementary Figure 13: forest plot the risk of hypovolemia (15 mg vs. 5 mg). CI: confidence interval; M-H: Mantel-Haenszel.

**Supplementary 14.** Supplementary Figure 14: forest plot of the risk of GMIs between 15 mg and 5 mg groups by gender. CI: confidence interval; M-H: Mantel-Haenszel.

**Supplementary 15.** Supplementary Table 1: a: leave-one-out sensitivity analysis for UTIs (ertugliﬂozin vs. control). b: sensitivity analysis by excluding two studies that were not placebo-controlled. RR: risk ratio; CI: confidence interval; NA: not available.

**Supplementary 16.** Supplementary Table 2: a: leave-one-out sensitivity analysis for drug-related adverse events (ertugliﬂozin vs. control). b: sensitivity analysis by excluding two studies that were not placebo-controlled. RR: risk ratio; CI: confidence interval; NA: not available.

**Supplementary 17.** Supplementary Table 3: a: leave-one-out sensitivity analysis for discontinuation related to adverse events (ertugliﬂozin vs. control). b: sensitivity analysis by excluding two studies that were not placebo-controlled. RR: risk ratio; CI: confidence interval; NA: not available.

**Supplementary 18.** Supplementary Table 4: a: leave-one-out sensitivity analysis for symptomatic hypoglycemia (ertugliﬂozin vs. control). b: sensitivity analysis by excluding two studies that were not placebo-controlled. RR: risk ratio; CI: confidence interval; NA: not available.

**Supplementary 19.** Supplementary Table 5: leave-one-out sensitivity analysis for deaths (ertugliﬂozin vs. control). RR: risk ratio; CI: confidence interval; NA: not available.

**Supplementary 20.** Supplementary Table 6: a: leave-one-out sensitivity analysis for hypovolemia (ertugliﬂozin vs. control). b: sensitivity analysis by excluding two studies that were not placebo-controlled. RR: risk ratio; CI: confidence interval; NA: not available.

**Supplementary 21.** Supplementary Table 7: a: leave-one-out sensitivity analysis for GMI (female vs. male). b: sensitivity analysis by excluding two studies that were not placebo-controlled. RR: risk ratio; CI: confidence interval; NA: not available.

**Supplementary 22.** Supplementary Table 8: leave-one-out sensitivity analysis for GMI (15 mg vs. 5 mg). RR: risk ratio; CI: confidence interval; NA: not available.

**Supplementary 23.** Supplementary Table 9: leave-one-out sensitivity analysis for UTI (15 mg vs. 5 mg). RR: risk ratio; CI: confidence interval; NA: not available.

**Supplementary 24.** Supplementary Table 10: leave-one-out sensitivity analysis for drug-related adverse events (15 mg vs. 5 mg). RR: risk ratio; CI: confidence interval; NA: not available.

**Supplementary 25.** Supplementary Table 11: leave-one-out sensitivity analysis for discontinuation related to adverse events (15 mg vs. 5 mg). RR: risk ratio; CI: confidence interval; NA: not available.

**Supplementary 26.** Supplementary Table 12: leave-one-out sensitivity analysis for deaths (15 mg vs. 5 mg). RR: risk ratio; CI: confidence interval; NA: not available.

**Supplementary 27.** Supplementary Table 13: leave-one-out sensitivity analysis for symptomatic hypoglycemia (15 mg vs. 5 mg). RR: risk ratio; CI: confidence interval; NA: not available.

**Supplementary 28.** Supplementary Table 14: leave-one-out sensitivity analysis for hypovolemia (15 mg vs. 5 mg). RR: risk ratio; CI: confidence interval; NA: not available.
Supplementary 29. Supplementary Table 15: quality of evidence for the risk of GMIs and UTIs (ertugliflozin 5 mg vs. control). High quality: we are very confident that the true effect lies close to that of the estimate of the effect. Moderate quality: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low quality: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. Very low quality: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. CI: confidence interval; RR: risk ratio. aThe sample size is small. bThe number of included studies is too small. All trials are funded by the pharmaceutical industry, which leads to a high risk of other biases. dPoint estimates vary widely from study to study. The 95% confidence interval includes no effect (i.e., confidence interval includes RR of 1.0).

Supplementary 30. Supplementary Table 16: quality of evidence for the risk of GMIs and UTIs (ertugliflozin 15mg vs. control). High quality: we are very confident that the true effect lies close to that of the estimate of the effect. Moderate quality: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low quality: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. Very low quality: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. CI: confidence interval; RR: risk ratio. aThe sample size is small. bThe number of included studies is too small. All trials are funded by the pharmaceutical industry, which leads to a high risk of other biases. dPoint estimates vary widely from study to study. The 95% confidence interval includes no effect (i.e., confidence interval includes RR of 1.0).

References

[1] P. Saeedi, I. Petersohn, P. Salpea et al., “Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition,” Diabetes Research and Clinical Practice, vol. 157, article 107843, 2019.

[2] S. E. Inzucchi, R. M. Bergenstal, J. B. Buse et al., “Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD),” Diabetesologia, vol. 55, no. 6, pp. 1577–1596, 2012.

[3] FDA, “FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes,” 2018, https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes.

[4] Medical Letter on Drugs and Therapeutics, “Ertugliflozin for type 2 diabetes,” JAMA, vol. 319, no. 23, pp. 2434-2435, 2018.

[5] A. J. Scheen, "Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus," Drugs, vol. 75, no. 1, pp. 33–59, 2015.

[6] J. Rosenstock, J. Frias, D. PålI et al., “Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET),” Diabetes Obesity & Metabolism, vol. 20, no. 3, pp. 520–529, 2018.

[7] S. Miller, T. Krumins, H. Zhou et al., “Ertugliflozin and sitagliptin co-initiation in patients with type 2 diabetes: the VERTIS SITA randomized study,” Diabetes Therapy, vol. 9, no. 1, pp. 253–268, 2018.

[8] A. M. McNeill, G. Davies, E. Kruger et al., “Ertugliflozin compared to other anti-hyperglycemic agents as monotherapy and add-on therapy in type 2 diabetes: a systematic literature review and network meta-analysis,” Diabetes Therapy, vol. 10, no. 2, pp. 473–491, 2019.

[9] J. Liu, L. Tarasenko, S. G. Terra et al., “Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: a pooled analysis of placebo-controlled studies,” Diabetes & Vascular Disease Research, vol. 16, no. 5, pp. 415–423, 2019.

[10] J. P. T. Higgins and S. Green, Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0, The Cochrane Collaboration, 2011.

[11] D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, and for the PRISMA Group, “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement,” BMJ, vol. 339, no. 1, article b2535, 2009.

[12] J. P. T. Higgins, D. G. Altman, P. C. Gotzsche et al., “The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials,” BMJ, vol. 343, p. 5928, 2011.

[13] G. H. Guyatt, A. D. Oxman, G. E. Vist et al., “GRADE: an emerging consensus on rating quality of evidence and strength of recommendations,” BMJ, vol. 336, no. 7650, pp. 924–926, 2008.

[14] L. Ji, Y. Liu, H. Miao et al., “Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia,” Diabetes, Obesity and Metabolism, vol. 21, no. 6, pp. 1474–1482, 2019.

[15] P. Hollander, J. Hill, J. Johnson et al., “Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin,” Current Medical Research and Opinion, vol. 35, no. 8, pp. 1335–1343, 2019.

[16] S. Gallo, B. Charbonnel, A. Goldman et al., “Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial,” Diabetes Obesity & Metabolism, vol. 21, no. 4, pp. 1027–1036, 2019.

[17] R. E. Pratley, R. Eldor, A. Raji et al., “Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial,” Diabetes, Obesity & Metabolism, vol. 20, no. 5, pp. 1111–1120, 2018.

[18] P. Hollander, J. Liu, J. Hill et al., “Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: the VERTIS FACTORIAL randomized trial,” Diabetologia, vol. 63, no. 4, pp. 955–966, 2020.

[19] S. Dagogo-Jack, J. Liu, R. Eldor et al., “Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: the
VERTIS SITA2 placebo-controlled randomized study,” *Diabetes Obesity & Metabolism*, vol. 20, no. 3, pp. 530–540, 2018.

[20] R. Aronson, J. Frias, A. Goldman, A. Darekar, B. Lauring, and S. G. Terra, “Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study,” *Diabetes Obesity & Metabolism*, vol. 20, no. 6, pp. 1453–1460, 2018.

[21] S. G. Terra, K. Focht, M. Davies et al., “Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone,” *Diabetes, Obesity & Metabolism*, vol. 19, no. 5, pp. 721–728, 2017.

[22] S. E. Geerlings and A. I. Hoepelman, “Immune dysfunction in patients with diabetes mellitus (DM),” *FEMS Immunology and Medical Microbiology*, vol. 26, no. 3-4, pp. 259–265, 1999.

[23] E. Ferrannini and A. Solini, “SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects,” *Nature Reviews Endocrinology*, vol. 8, no. 8, pp. 495–502, 2012.

[24] H. Yokoyama, A. Nagao, S. Watanabe, and J. Honjo, “Incidence and risk of vaginal candidiasis associated with sodium-glucose co-transporter 2 inhibitors in real-world practice for women with type 2 diabetes,” *Journal of Diabetes Investigation*, vol. 10, no. 2, pp. 439–445, 2019.

[25] S. E. Geerlings, E. C. Brouwer, W. Gaastra, J. Verhoef, and A. L. M. Hoepelman, “Effect of glucose and pH on uropathogenic and non-uropathogenic Escherichia coli studies with urine from diabetic and non-diabetic individuals,” *Journal of Medical Microbiology*, vol. 48, no. 6, pp. 535–539, 1999.

[26] M. Mirabelli, E. Chieffari, P. Caroleo et al., “Long-term effectiveness and safety of SGLT-2 inhibitors in an Italian cohort of patients with type 2 diabetes mellitus,” *Journal Diabetes Research*, vol. 2019, article 3971060, 8 pages, 2019.

[27] D. Li, T. Wang, S. Shen, Z. Fang, Y. Dong, and H. Tang, “Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials,” *Diabetes, Obesity & Metabolism*, vol. 19, no. 3, pp. 348–355, 2017.

[28] J. R. Donnan, C. A. Grandy, E. Chibrikov et al., “Dose response of sodium glucose co-transporter-2 inhibitors in relation to urinary tract infections: a systematic review and network meta-analysis of randomized controlled trials,” *CMAJ Open*, vol. 6, no. 4, pp. 594–602, 2018.

[29] R. Santer and J. Calado, “Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target,” *Clinical Journal of the American Society of Nephrology*, vol. 5, no. 1, pp. 133–141, 2010.

[30] Z. Jingfan, L. Ling, L. Cong, L. Ping, and C. Yu, “Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on metformin: a meta-analysis,” *Archives of Endocrinology and Metabolism*, vol. 63, no. 5, pp. 478–486, 2019.

[31] J. Liu, L. Li, S. Li et al., “Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis,” *Scientific Reports*, vol. 7, no. 1, p. 2824, 2017.

[32] J. H. Y. Wu, C. Foote, J. Blomster et al., “Effects of sodium-glucose co-transporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis,” *The Lancet Diabetes and Endocrinology*, vol. 4, no. 5, pp. 411–419, 2016.

[33] X. Zhao, Y. Cui, S. Zhao et al., “Pharmacokinetic and pharmacodynamic properties and tolerability of single- and multiple-dose once-daily empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Chinese patients with type 2 diabetes mellitus,” *Clinical Therapeutics*, vol. 37, no. 7, pp. 1493–1502, 2015.

[34] K. Rådholm, Z. Zhou, K. Clemens, B. Neal, and M. Woodward, “Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men,” *Diabetes, Obesity & Metabolism*, vol. 22, no. 2, pp. 263–266, 2019.

[35] A. P. McGovern, M. Hogg, B. M. Shields et al., “Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation,” *BMJ Open Diabetes Research & Care*, vol. 8, no. 1, article e001238, 2020.

[36] N. Katsiki, N. Papanas, and D. P. Mikhailidis, “Dapagliflozin more than just another oral glucose-lowering agent,” *Expert Opinion on Investigational Drugs*, vol. 19, no. 12, pp. 1581–1589, 2010.

[37] W. L. Bennett, N. M. Maruthur, S. Singh et al., “Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations,” *Annals of Internal Medicine*, vol. 154, no. 9, pp. 602–613, 2011.

[38] W. T. Cefalu, L. A. Leiter, K. H. Yoon et al., “Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial,” *The Lancet*, vol. 382, no. 9896, pp. 941–950, 2013.